Abstract:
A method, device and system disclosed used in storage technique, comprising: splitting a file of size M into k blocks, that is to say, each block is of size M/k; issuing the above k blocks across k different storage nodes in the distributed network storage system in a distributed manner; using the k blocks, constructing n−k independent blocks via linear coding method, and satisfying the property that any k of the n encoded blocks can be used to reconstruct the original data in the file, which means the linear coding method is a kind of Maximum-Distance Separable (MDS) code; distribute the n−k encoded blocks to the rest n−k different storage codes in the distributed network storage systems.
Abstract:
Provided is a fusion protein comprising circularly permuted form of TRAIL, and the fusion protein contains circularly permuted form of TRAIL and oligopeptides located at the N-terminus and/or C-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines. The components of the circularly permuted form of TRAIL from N-terminus to C-terminus are: (a) amino acids 135-281 of TRAIL, (b) a linker, and (c) amino acids 121-135 of TRAIL or amino acids 114-135 of TRAIL or amino acids 95-135 of TRAIL or any fragments of amino acids 95-135 of TRAIL containing amino acids 121-135 of TRAIL. Also provided is a method for treating cancer by using the fusion protein.
Abstract:
The present invention relates to a method for early evaluation of clinical efficacy of antitumor intervention measure, comprising evaluating the efficacy of the antitumor intervention measure by assaying whether the content of a tumor-damaging biomarker(s) in the blood of a patient having tumor rises as compared to the baseline level before treatment within a time window after the patients receives at least one antitumor intervention measure. In preferable embodiments, the tumor-damaging biomarker(s) is selected from a group consisting of Alanine Aminotransferase (ALT), Aspartate Transaminase (AST), Lactate Dehydrogenase (LDH); said tumor is multiple myeloma; said antitumor intervention measure is the administration of CPT alone or the administration of CPT in combination with thalidomide.
Abstract:
A method and system are provided for trending a coronary burden such as an ischemic burden or acute myocardial infarction (AMI) for a patient. Trending provides obtaining cardiac data over a period of time, identifying the onset and the termination of coronary episodes based on a ST segment variation within the cardiac data, recording coronary burden information, and presenting the coronary burden information to a user. The coronary burden information may include the number of coronary episodes occurring over a period of time, the time duration of the coronary episodes, and the maximum ST segment variations for the coronary episodes that occur over a period of time.
Abstract:
A method for modeling power management in an integrated circuit (IC) includes: specifying a circuit design and a power architecture for the IC, the power architecture including a plurality of power domains for specifying power levels in different portions of the IC; determining an emulation module for the IC by including one or more hardware elements for modeling the power architecture in the emulation module; and using the emulation module to simulate changing power levels in one or more power domains of the IC including a power shutoff in at least one power domain.
Abstract:
A method of analyzing power consumption for a DUT (device under test) that includes an integrated circuit or an electronic system includes: providing emulation data for states of the DUT in one or more time windows; determining operational mode values from the emulation data and a selection of operational modes that characterize circuit behavior in the one or more time windows; dividing each time window into one or more segments based on at least one power criterion; determining power-activity values for the one or more segments; determining power-consumption values for the one or more segments from the power-activity values; using the power-activity values and the power-consumption values to determine relative power activity across the one or more segments and adjusting the one or more segments to target high power activity over operational modes in the one or more time windows; and saving one or more values for power activity of the DUT in a computer-readable medium.
Abstract:
Cardiac activity is sensed over a plurality of heart beats defining a beat set. For each beat in the set, it is determined whether the beat is a non-classified beat (e.g., paced beat, a beat outside of a specified heart rate range or a PVC), or a classified beat. For each classified beat, it is determined whether the beat is a non-detect beat, a minor beat or a major beat. Counts of classified beats, non-classified beats, major beats, minor beats, and non-detect beats are maintained. The beat set is declared to be one of a non-classified set, a major set, a minor set or a non-detect set based on the relative counts of classified beats, non-classified beats, major beats, minor beats, and non-detect beats. Over a period of time, counts of beat-set types are maintained and entry into and exit from ST episodes are determined based on these beat-set counts.
Abstract:
A method and system are provided for trending variation in coronary burden across multiple heart rate ranges. The method and system include obtaining cardiac signals having a segment of interest over a period of time where each cardiac signal has an associated heart rate that falls within at least one heart rate range. Segment variations of the segment of interest are determined and grouped based on the associated heart rates to produce distributions of segment variations that are associated with the heart rate ranges. Trending information is produced by automatically comparing the distributions of segment variations between different heart rate ranges.
Abstract:
The present invention provides a fusion protein comprising an immunostimulatory polypeptide and a mutant E7 protein of a human papilloma virus. The present invention also provides a gene encoding the fusion protein, expression vectors containing the gene, a pharmaceutical composition comprising the fusion protein, a method for treating or preventing a human papilloma virus related disease by using the fusion protein and uses of the fusion protein in the preparation of a medicament for the treatment or prevention of the human papilloma virus related disease.
Abstract:
A method and system are provided for tracking ST shift data. The system includes an implantable medical device having an input configured to receive cardiac signals. Each cardiac signal has an associated heart rate and includes a segment of interest. The implantable medical device further includes a processor configured to determine segment variations of the segment of interest in the cardiac signals. The processor determines a heart rate associated with each of the segment variations with each heart rate falling within a corresponding heart rate range. The implantable medical device also includes a memory configured to store a group of histograms for a corresponding group of heart rate ranges. The histograms store distributions for the segment variations within corresponding heart rate ranges.